JPWO2021174208A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021174208A5 JPWO2021174208A5 JP2022552141A JP2022552141A JPWO2021174208A5 JP WO2021174208 A5 JPWO2021174208 A5 JP WO2021174208A5 JP 2022552141 A JP2022552141 A JP 2022552141A JP 2022552141 A JP2022552141 A JP 2022552141A JP WO2021174208 A5 JPWO2021174208 A5 JP WO2021174208A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cancer
- cell
- tumor
- cell population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 183
- 238000000034 method Methods 0.000 claims description 137
- 210000004027 cell Anatomy 0.000 claims description 110
- 206010028980 Neoplasm Diseases 0.000 claims description 98
- 239000000523 sample Substances 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 49
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 206010006187 Breast cancer Diseases 0.000 claims description 29
- 208000026310 Breast neoplasm Diseases 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 230000004913 activation Effects 0.000 claims description 22
- 206010009944 Colon cancer Diseases 0.000 claims description 20
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 20
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 18
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 18
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 18
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 16
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 16
- 108010002350 Interleukin-2 Proteins 0.000 claims description 15
- 210000004698 lymphocyte Anatomy 0.000 claims description 15
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 14
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 14
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 14
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 14
- 201000004101 esophageal cancer Diseases 0.000 claims description 14
- 206010017758 gastric cancer Diseases 0.000 claims description 14
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 14
- 201000011549 stomach cancer Diseases 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 14
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 12
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 9
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 8
- 230000006862 enzymatic digestion Effects 0.000 claims description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 206010014733 Endometrial cancer Diseases 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 7
- 230000003416 augmentation Effects 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 7
- 201000010536 head and neck cancer Diseases 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 7
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 206010046766 uterine cancer Diseases 0.000 claims description 7
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 6
- 102100032937 CD40 ligand Human genes 0.000 claims description 6
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 6
- 239000006285 cell suspension Substances 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 6
- 206010069754 Acquired gene mutation Diseases 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 230000037439 somatic mutation Effects 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 3
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 3
- 102000049320 CD36 Human genes 0.000 claims description 3
- 108010045374 CD36 Antigens Proteins 0.000 claims description 3
- 108010029697 CD40 Ligand Proteins 0.000 claims description 3
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 3
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 3
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 3
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 3
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims description 3
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 102100022341 Integrin alpha-E Human genes 0.000 claims description 3
- 102000017578 LAG3 Human genes 0.000 claims description 3
- 101150030213 Lag3 gene Proteins 0.000 claims description 3
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 239000002771 cell marker Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002577 cryoprotective agent Substances 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 15
- 239000000158 apoptosis inhibitor Substances 0.000 description 15
- 108091007065 BIRCs Proteins 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 102100027515 Baculoviral IAP repeat-containing protein 6 Human genes 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 3
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 3
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102100029855 Caspase-3 Human genes 0.000 description 2
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 1
- SUUHZYLYARUNIA-YEWWUXTCSA-N (3s)-5-fluoro-3-[[(2s)-2-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 SUUHZYLYARUNIA-YEWWUXTCSA-N 0.000 description 1
- HKIPCXRNASWFRU-UHFFFAOYSA-N 1,3-difluoropropan-2-one Chemical compound FCC(=O)CF HKIPCXRNASWFRU-UHFFFAOYSA-N 0.000 description 1
- XDHJBIYJRNFDKS-IBGZPJMESA-N 1-[(4-methoxyphenyl)methyl]-5-[(2s)-2-(pyridin-3-yloxymethyl)pyrrolidin-1-yl]sulfonylindole-2,3-dione Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=C(S(=O)(=O)N3[C@@H](CCC3)COC=3C=NC=CC=3)C=C2C(=O)C1=O XDHJBIYJRNFDKS-IBGZPJMESA-N 0.000 description 1
- GNCZTZCPXFDPLI-UHFFFAOYSA-N 4-chloro-2-[[oxo-[3-(trifluoromethyl)anilino]methyl]amino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 GNCZTZCPXFDPLI-UHFFFAOYSA-N 0.000 description 1
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 1
- 102100021676 Baculoviral IAP repeat-containing protein 1 Human genes 0.000 description 1
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 101710178008 Baculoviral IAP repeat-containing protein 6 Proteins 0.000 description 1
- 102100027517 Baculoviral IAP repeat-containing protein 8 Human genes 0.000 description 1
- 101150104237 Birc3 gene Proteins 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102000004068 Caspase-10 Human genes 0.000 description 1
- 108090000572 Caspase-10 Proteins 0.000 description 1
- 102000004046 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 101000896156 Homo sapiens Baculoviral IAP repeat-containing protein 1 Proteins 0.000 description 1
- 101000936081 Homo sapiens Baculoviral IAP repeat-containing protein 6 Proteins 0.000 description 1
- 101000936076 Homo sapiens Baculoviral IAP repeat-containing protein 8 Proteins 0.000 description 1
- 101000804865 Homo sapiens E3 ubiquitin-protein ligase XIAP Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010052550 MDL 201053 Proteins 0.000 description 1
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 241000566576 Tyto Species 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 1
- GBJVAVGBSGRRKN-JYEBCORGSA-N Z-DEVD-FMK Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)OC)NC(=O)[C@H](CC(=O)OC)NC(=O)OCC1=CC=CC=C1 GBJVAVGBSGRRKN-JYEBCORGSA-N 0.000 description 1
- 229950004993 asunercept Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010071933 benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone Proteins 0.000 description 1
- 108010088607 benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone Proteins 0.000 description 1
- ASXVEBPEZMSPHB-YJBOKZPZSA-N benzyl n-[(2s)-1-[[(2s)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)CF)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 ASXVEBPEZMSPHB-YJBOKZPZSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- ANTIWMNLIROOQF-UHFFFAOYSA-N methyl 5-fluoro-3-[2-[[2-[[4-methoxy-2-[[3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]propanoylamino]-4-oxopentanoate Chemical compound COC(=O)CC(C(=O)CF)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(CC(=O)OC)NC(=O)C(C(C)C)NC(=O)OCC1=CC=CC=C1 ANTIWMNLIROOQF-UHFFFAOYSA-N 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- -1 respectively) Proteins 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- XQDCKJKKMFWXGB-UHFFFAOYSA-N wedelolactone Chemical compound O1C2=CC(O)=C(O)C=C2C2=C1C1=C(O)C=C(OC)C=C1OC2=O XQDCKJKKMFWXGB-UHFFFAOYSA-N 0.000 description 1
- RFQPHWCAHNTCDX-UHFFFAOYSA-N wedelolactone Natural products COc1cc(O)cc2OC(=O)c3c(oc4cc(O)c(O)cc34)c12 RFQPHWCAHNTCDX-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062982704P | 2020-02-27 | 2020-02-27 | |
US62/982,704 | 2020-02-27 | ||
PCT/US2021/020320 WO2021174208A1 (fr) | 2020-02-27 | 2021-03-01 | Procédés d'enrichissement et d'expansion ex vivo de lymphocytes t réactifs à une tumeur et compositions associées |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023516636A JP2023516636A (ja) | 2023-04-20 |
JPWO2021174208A5 true JPWO2021174208A5 (fr) | 2024-03-12 |
Family
ID=75143768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022552141A Pending JP2023516636A (ja) | 2020-02-27 | 2021-03-01 | 腫瘍反応性t細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4110799A1 (fr) |
JP (1) | JP2023516636A (fr) |
KR (1) | KR20220158727A (fr) |
CN (1) | CN115427438A (fr) |
AU (1) | AU2021226903A1 (fr) |
BR (1) | BR112022016490A2 (fr) |
CA (1) | CA3172902A1 (fr) |
IL (2) | IL295934A (fr) |
MX (1) | MX2022010517A (fr) |
WO (1) | WO2021174208A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110452870A (zh) * | 2019-05-20 | 2019-11-15 | 河南省肿瘤医院 | 一种肿瘤特异性t细胞的分离培养方法及由其获得的产品 |
WO2023220128A1 (fr) * | 2022-05-10 | 2023-11-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Ciblage de cellules myéloïdes suppressives (mdsc) dans le cancer de la vessie pour améliorer l'efficacité d'une thérapie cellulaire adoptive (act) |
WO2023229979A1 (fr) * | 2022-05-22 | 2023-11-30 | Skdw Holdings, Llc | Méthodes d'isolement et d'amélioration de populations de lymphocytes réactifs à une tumeur |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
US5891434A (en) | 1991-06-17 | 1999-04-06 | Centocor, Inc. | Monoclonal antibodies to the APO-1 antigen |
DE69332981T2 (de) | 1992-10-23 | 2004-05-19 | Immunex Corp., Seattle | Methoden zur herstellung löslicher, oligomerer proteine |
FI934751A (fi) | 1992-10-30 | 1994-05-01 | Bristol Myers Squibb Co | Extracellulaera matrisreceptorligander som modulerar leukocytfunktioner |
US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
US5691188A (en) | 1994-02-14 | 1997-11-25 | American Cyanamid Company | Transformed yeast cells expressing heterologous G-protein coupled receptor |
DE4447484C2 (de) | 1994-04-08 | 1997-07-17 | Deutsches Krebsforsch | Mittel zur Hemmung von Apoptose |
ATE226641T1 (de) | 1995-04-08 | 2002-11-15 | Lg Chemical Ltd | Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie |
DE69733773T2 (de) | 1996-05-02 | 2006-04-20 | Mochida Pharmaceutical Co. Ltd. | Fas ANTIGEN-DERIVATE |
US5985565A (en) | 1996-10-09 | 1999-11-16 | Temple University-Of The Commonwealth System Of Higher Education | Chronic fatigue syndrome diagnosis |
US6210669B1 (en) | 1996-10-11 | 2001-04-03 | Bristol-Myers Squibb Co. | Methods and compositions for immunomodulation |
US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
WO1999044330A1 (fr) | 1998-02-24 | 1999-09-02 | Otkrytoe Aktsionernoe Obschestvo 'moskovskaya Gorodskaya Telefonnaya Set' | Procede de cryptage en bloc de donnees discretes |
HUP0102067A2 (hu) | 1998-03-30 | 2001-10-28 | Eli Lilly And Co. | A TNF receptorcsaládba tartozó érett FLINT (mFLINT) polipeptid vagy más néven az OPG3 terápiás alkalmazásai |
AU4772299A (en) | 1998-06-18 | 2000-01-05 | Karolinska Innovations Ab | Fas peptides and antibodies for modulating apoptosis |
DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
PL375144A1 (en) | 2002-07-30 | 2005-11-28 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
SI1606318T1 (sl) | 2003-03-26 | 2009-12-31 | Apogenix Gmbh | Izboljšani Fc fuzijski proteini |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
EP3363907A1 (fr) | 2004-05-27 | 2018-08-22 | The Trustees of the University of Pennsylvania | Nouvel antigène artificiel présentant des cellules et utilisations associées |
CA2585776A1 (fr) | 2004-10-29 | 2006-05-11 | University Of Southern California | Poly-immunotherapie anticancereuse dans laquelle sont utilisees des molecules co-stimulatrices |
ES2432091T5 (es) | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
SI1877090T1 (sl) | 2005-05-06 | 2014-12-31 | Providence Health System | Trimerni fuzijski protein OY40-imunoglobulina in postopki uporabe |
CA2970873C (fr) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies |
US7596024B2 (en) | 2006-07-14 | 2009-09-29 | Semiconductor Energy Laboratory Co., Ltd. | Nonvolatile memory |
EP1894940A1 (fr) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | Protéines de fusion de la superfamille TNF |
KR20100014588A (ko) | 2007-02-27 | 2010-02-10 | 제넨테크, 인크. | 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 |
EP3222634A1 (fr) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Anticorps dirigés contre le récepteur humain de mort programmée pd-1 |
CA2860950C (fr) | 2007-07-10 | 2017-08-01 | Apogenix Gmbh | Proteines de fusion collectines de la superfamille des tnf |
PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
EP2540740B1 (fr) | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Récepteurs multimériques TNF |
SI2310509T1 (sl) | 2008-07-21 | 2015-07-31 | Apogenix Gmbh | TNFSF enoverižne molekule |
US8475790B2 (en) | 2008-10-06 | 2013-07-02 | Bristol-Myers Squibb Company | Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
ES2593049T3 (es) | 2009-01-09 | 2016-12-05 | Apogenix Ag | Proteínas de fusión que forman trímeros |
CN102421913A (zh) | 2009-03-13 | 2012-04-18 | 宾夕法尼亚大学董事会 | Ox40/trail融合蛋白 |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
KR101573109B1 (ko) | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
IL300733A (en) | 2010-03-05 | 2023-04-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeting immune modulation |
US20120213771A1 (en) | 2010-04-13 | 2012-08-23 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
NZ623807A (en) | 2010-04-13 | 2016-03-31 | Celldex Therapeutics Inc | Antibodies that bind human cd27 and uses thereof |
WO2011149534A2 (fr) | 2010-05-25 | 2011-12-01 | The Regents Of The University Of California | Bambam : analyse comparative parallèle de données de séquençage à haut rendement |
US9646134B2 (en) | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
AU2011275749C1 (en) | 2010-07-09 | 2015-09-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to CD27 |
MY171312A (en) | 2010-08-23 | 2019-10-08 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
WO2012129201A1 (fr) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Procédés de mise en croissance de lymphocytes infiltrant une tumeur dans contenants perméables au gaz |
WO2012177788A1 (fr) | 2011-06-20 | 2012-12-27 | La Jolla Institute For Allergy And Immunology | Modulateurs de 4-1bb et réponses immunitaires |
AU2012299421B2 (en) | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
WO2013039954A1 (fr) | 2011-09-14 | 2013-03-21 | Sanofi | Anticorps anti-gitr |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
KR102201694B1 (ko) | 2012-07-18 | 2021-01-12 | 아포게닉스 아게 | CD95-Fc 이소형의 혼합물을 포함하는 조성물 |
BR112015021414B1 (pt) | 2013-03-14 | 2020-11-10 | Icahn School Of Medicine At Mount Sinai | vírus da doença newcastle e seus usos |
SG11201507781VA (en) | 2013-03-18 | 2015-10-29 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
AU2014364606A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
ES2783026T3 (es) | 2014-02-04 | 2020-09-16 | Pfizer | Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer |
AU2014407539B2 (en) | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
JP6599450B2 (ja) | 2014-10-02 | 2019-10-30 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するt細胞を単離する方法 |
US20180044429A1 (en) | 2015-03-09 | 2018-02-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
BR112019008305A2 (pt) * | 2016-10-26 | 2019-08-06 | Iovance Biotherapeutics Inc | métodos para expansão de linfócitos infiltrantes de tumor, para avaliação da atividade metabólica de uma população de células til, para tratamento de um sujeito com câncer e para ensaiar tils, e, população de tils expandidos |
US20210137930A1 (en) * | 2018-02-13 | 2021-05-13 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
US20210046119A1 (en) * | 2018-04-20 | 2021-02-18 | Children's National Medical Center | Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer |
-
2021
- 2021-03-01 EP EP21713843.7A patent/EP4110799A1/fr active Pending
- 2021-03-01 JP JP2022552141A patent/JP2023516636A/ja active Pending
- 2021-03-01 KR KR1020227033442A patent/KR20220158727A/ko unknown
- 2021-03-01 CN CN202180030269.2A patent/CN115427438A/zh active Pending
- 2021-03-01 WO PCT/US2021/020320 patent/WO2021174208A1/fr unknown
- 2021-03-01 BR BR112022016490A patent/BR112022016490A2/pt unknown
- 2021-03-01 CA CA3172902A patent/CA3172902A1/fr active Pending
- 2021-03-01 MX MX2022010517A patent/MX2022010517A/es unknown
- 2021-03-01 IL IL295934A patent/IL295934A/en unknown
- 2021-03-01 AU AU2021226903A patent/AU2021226903A1/en active Pending
- 2021-03-01 IL IL295990A patent/IL295990A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230099491A1 (en) | Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells | |
US11787848B2 (en) | CD33 specific chimeric antigen receptors | |
US11673953B2 (en) | DLL3 targeting chimeric antigen receptors and binding agents | |
US20230242878A1 (en) | Expansion of gamma delta t cells, compositions, and methods of use thereof | |
EP3858856A1 (fr) | Anticorps monoclonal anti-b7-h3 et son utilisation en thérapie cellulaire | |
TW202011999A (zh) | Dll3 的嵌合受體及其使用方法 | |
CN110494158A (zh) | 使用包含优化的多功能t细胞的嵌合受体t细胞进行治疗 | |
KR20200130324A (ko) | Cd83-결합 키메라 항원 수용체 | |
IL295934A (en) | Methods for in vitro enrichment and expansion of tumor reactive t cells and related preparations | |
CN107106609A (zh) | 刺激和扩展t细胞的组合物和方法 | |
JPWO2021174208A5 (fr) | ||
US20220184124A1 (en) | Methods and reagents for characterizing car t cells for therapies | |
EP3959235B1 (fr) | Récepteurs d'antigènes chimériques résistant au rituximab et leurs utilisations | |
US20200339944A1 (en) | Methods of manufacturing allogeneic car t cells | |
JPWO2020205662A5 (fr) | ||
US20220241329A1 (en) | Formulations and processes for car t cell drug products | |
US20240085403A1 (en) | Method for inhibiting adventitious viral infection | |
WO2002032463A1 (fr) | Methodes de traitement des cancers par stimulation de cellules dendritiques ou de lymphomes avec certaines molecules tnf | |
EA044224B1 (ru) | ЭКСПАНСИЯ γδ-T-КЛЕТОК, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |